COPENHAGEN (Reuters) - Novo Nordisk NOVOb.CO said on Thursday it has filed litigation in a Delaware district court against Mylan MYL.O aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.
“We can confirm that Novo Nordisk has filed a lawsuit against Mylan for patent infringement of Victoza,” the company said in an e-mail.
The news was first reported by Bloomberg.
Reporting by Andreas Mortensen; editing by Jason Neely
Our Standards: The Thomson Reuters Trust Principles.